News Search Year - Any - 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 2008 November 5, 2026 Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial November 5, 2026 Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial October 26, 2026 Expert Video Summary: Results of an Exploratory ctDNA Biomarker Analysis in Advanced GIST October 26, 2026 IGNITE: A Phase III Study of Tirabrutinib Versus Rituximab and Temozolomide Combination Therapy in Relapsed/Refractory Primary Central Nervous System Lymphoma October 26, 2026 Vimseltinib for Patients With Tenosynovial Giant Cell Tumor: A Multicenter, Open-Label, Phase 2 Trial
November 5, 2026 Communicating Change on Multi-item Patient-Reported Outcome Measures: What Were the Meaningful Changes in Physical Functioning Experienced by Patients on Vimseltinib in the MOTION Trial
November 5, 2026 Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial
October 26, 2026 Expert Video Summary: Results of an Exploratory ctDNA Biomarker Analysis in Advanced GIST
October 26, 2026 IGNITE: A Phase III Study of Tirabrutinib Versus Rituximab and Temozolomide Combination Therapy in Relapsed/Refractory Primary Central Nervous System Lymphoma
October 26, 2026 Vimseltinib for Patients With Tenosynovial Giant Cell Tumor: A Multicenter, Open-Label, Phase 2 Trial
